Glucocorticoids (GC) are important lipid hormones that are involved in the regulation of stress responses, metabolism and immune homeostasis ([@bib43]). While the adrenal glands are the major source of GC, it is now recognised that GC synthesis occurs at other sites ([@bib39]), such as the thymus ([@bib59]), brain ([@bib35]; [@bib13]), prostate gland ([@bib21]), vascular endothelium ([@bib51]), intestinal epithelium ([@bib45]) and epidermis ([@bib49]; [@bib16]). In the skin, steroidogenesis is involved in the modulation of a variety of physiological functions ([@bib50]; [@bib60]; [@bib31]). Recently, we characterised the oral GC system in detail and showed that the local concentration of active cortisol in normal keratinocytes had the capacity to modulate disease progression in conditions where steroids are used routinely as a treatment modality ([@bib9]; [@bib10]). These findings raise the possibility that steroidogenesis may also play a key role in carcinogenesis, possibly through autocrine and paracrine mechanisms. Given the known immunomodulatory function of cortisol, we wished to examine whether local non-adrenal steroids had the capacity to modulate anti-cancer immune responses.

Regulation of neuroendocrine function occurs primarily through the control of the production and degradation of steroid hormones ([@bib49]). Activation of the steroid cortisone to cortisol occurs via 11*β*-hydroxysteroid dehydrogenase (HSD) 1 (*HSD11B1* gene; [@bib58]) whereas the reverse, cortisol to cortisone, involves 11*β*-HSD2 (*HSD11B2* gene; [@bib34]). 11*β*-HSDs, therefore, are key enzymes in the tissue-specific regulation of GC and current thinking suggests that their deregulation is associated with a variety of pathological processes in the skin ([@bib16]; [@bib60]; [@bib10]). While the role of 11*β*-HSD1 is well documented in epidermal physiology ([@bib52]; [@bib56]; [@bib22]; [@bib28]; [@bib54]; [@bib57]), little is known about the role of 11*β*-HSD2 in skin keratinocytes. Clarification of the function of 11*β*-HSD2 in epidermal keratinocytes may have major clinical implications because of the therapeutic relevance of corticosteroid agents in the management of many skin disorders ([@bib23]).

In the present study, we assessed cortisol production in a broad spectrum of cell and tissue types. We show that cortisol levels correlated with inhibition of proliferation among tumour-specific CD8^+^ T lymphocytes. Using immunohistochemical analysis of cancer samples, we demonstrated alterations of 11*β*-HSD enzymes in a large number of tissue types, including skin squamous cell carcinoma (SCC). The role of 11*β*-HSD2 in normal and malignant keratinocytes was also investigated using functional assays of metabolism, adhesion and scattering from three-dimensional aggregates. The data demonstrate for the first time that 11*β*-HSD2 plays a key role in the pathophysiology of malignant epidermal cells.

Materials and methods
=====================

Antibodies and chemicals
------------------------

Antibodies against residues 261--405 of human 11*β*-HSD2 (clone H-145), and amino acids 65--164 of 11*β*-HSD1 (clone H-100), anti-tubulin, horseradish peroxidase-conjugated and FITC-conjugated anti-rabbit IgGs and 18*β*-glycyrrhetinic acid (18*β*-GA) were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Nitrocellulose membranes, keratinocyte growth medium and antibiotics/anti-mycotics were obtained from Invitrogen (Paisley, UK). Reagents for enhanced chemiluminescence and films were obtained from Amersham Biosciences (Buckinghamshire, UK) and the reagents for protein extraction and cell culture were obtained from Sigma (Sigma-Aldrich, Gillingham, Dorset, UK).

Cells and culture conditions
----------------------------

A broad spectrum (*n*=16) of normal and malignant cell lines from eight different tissue types were used in this study including prostate (DU145, PC3, VCaP, LNCaP), bladder (T24, RT4), breast (MCF-7), colorectal (HT29, SW620, SWH80), renal (mouse RenCA WT) and pancreas (HUp-T3; a kind gift from Professor Chris Paraskeva, School of Cellular and Molecular Medicine, University of Bristol, UK). These cells were validated using karyotypic analysis prior to use. These cells retained their phenotype and function, together with their growth characteristics *in vitro*, throughout the 3 months that they were routinely kept in continuous culture. HaCaT cells are a strain of immortalised human skin keratinocytes that have an active steroid metabolism ([@bib9]) and display normal differentiation *in vivo* ([@bib5]; [@bib36]). HaCaT c-Ha-ras-transfected clones (I-7, II-3, and RT-3; [@bib15]) were kind gifts from Professor Norbert Fusenig (DKFZ, Heidelberg, Germany). Following subcutaneous transplantation to athymic mice, HaCaT cells are non-tumourigenic, I-7 cells form non-invasive epidermoid cysts, II-3 cells form primary SCCs with minimal metastatic dissemination and RT-3 cells, the most aggressive cell type, form large SCCs at the site of inoculation and have widespread metastatic dissemination (Fusening and Boukamp, 1998). The cells are widely used as a model of epidermal cancer progression ([@bib14]) and were last authenticated prior to commencing the experiments in 2012 with mRNA microarrays. The oral SCC cell strain (H357) underwent full genome sequencing in 2016 whereas the skin SCC cell line A431 was purchased from Sigma-Aldrich.

All of the cell lines/strains were derived prior to 2001 and, therefore, were not subject to Ethical Committee approval in the UK. The cells were placed in serum-free DMEM/F12 for 24 h before the collection of supernatants for cortisol assessment; RT-3 was cultured in media containing 400 mg ml^−1^ geneticin sulphate (G418; PAA laboratories, Leeds, UK). At the time of experimentation, cells were seeded in 35-mm Petri plastic dishes and grown to confluence. Cells were grown in a humidified atmosphere of 5% CO~2~/air at 37 °C. Ethics committee approvals were obtained for this study both in Bristol (E5133) and in Melbourne (1340716.1), and high standards of ethics were applied in carrying out all of the investigations.

Multicellular aggregates (MCAs) were prepared according to published protocols ([@bib30]). To generate MCAs, cell monolayers were first treated with EDTA to prepare single cell suspensions and then, the cells were seeded onto polyhydroxylethyl-methacrylate (poly-HEMA)-coated 60-mm dishes (6 × 10^5^ cells per dish) in the presence of serum-free DMEM for 12 h, with or without 0.5% (w/v) 18*β*-GA. Unlike malignant keratinocytes ([@bib30]), the culture of normal keratinocytes for prolonged periods (e.g. 24 h) in the absence of extracellular cell matrixattachment resulted in significant cell death and non-viable MCAs (data not shown).

Tumour-specific CD8^+^ T lymphocyte proliferation *in vitro*
------------------------------------------------------------

Using anti-CD8 MACS midiMACS (Miltenyi Biotec, Bisley, UK), single-cell suspensions of peripheral lymph node and spleen cells from CL4 TcR-transgenic mice were enriched for naïve CD8^+^ T lymphocytes that recognised a tumour-specific antigen ([@bib25]). Anti-CD3 monoclonal antibody (10 *μ*g ml^−1^) was added to triplicate wells of 96-well rounded plates in a total volume of 50 *μ*l 1 × PBS and incubated in a 5% vol./vol. CO~2~ humidified atmosphere at 37 °C for 1.5 h; control wells contained 1 × PBS only. Plates were washed three times with 300 *μ*l 1 × PBS. In certain experiments, cortisol (10--1000 ng ml^−1^) was added to the wells. 5 × 10^4^ purified naïve, CL4, CD8^+^ T lymphocytes were added to each well and were cultured in a 5% vol./vol. CO~2~ humidified atmosphere at 37 °C for 72 h and pulsed with 1 *μ*Ci per well ^3^H-thymidine (Amersham BioSciences, Buckinghamshire, UK) in 25 *μ*l serum-free culture media for the last 8 h. Cells were harvested on fibre filters (Filtermats; COX Scientific Ltd., Kettering, UK) using a 24-well harvester (Skatron, Flow Laboratories, Oslo, Norway). Fibre filters were then dried and sealed into bags with 3 ml Betaplate Scint (Wallac Oy, Turku, Finland). ^3^H-thymidine incorporation was read by a 1450 Microbeta liquid scintillation counter for windows 2.7 (Wallac Oy). Data were analysed using Microsoft Office Excel and Prism 4.03 software (Graphpad).

siRNA transfection experiments
------------------------------

11*β*-HSD-directed siRNA pools and the negative-control pool were transfected as described previously ([@bib9]). The efficiency of transfection was monitored by western blotting (WB) of 11*β*-HSD1/2 expression.

Western blotting
----------------

For the assessment of protein levels, WB on whole-cell lysates and in-cell WB on culture monolayers was undertaken using standard procedures ([@bib8]). For all WB, a 1 : 500 dilution was used for the primary antibodies and the species-specific secondary IgG was diluted to 1 : 5000.

Enzyme-linked immunosorbent assay
---------------------------------

For quantification of cortisol levels with conventional enzyme-linked immunosorbent assay (ELISA), the conditioned media were collected at time points specified in the Results. Cortisol concentrations were measured with a Cortisol Parameter Assay Kit (R&D Systems, Minneapolis, MN, USA) and quantified at 415 nm with the ELx808 Microplate Reader (BioTek Instruments, Inc., Winooski, VT, USA).

Immunohistochemistry
--------------------

Skin tissue microarrays (Cat. No. SK483, multiple skin SCC tissue arrays; US Biomax, Rockville, MD, USA) and formalin-fixed, paraffin-embedded skin biopsies from individuals with SCC, melanoma, and without skin disease were subjected to immunohistochemical analyses, as described previously ([@bib42]; [@bib27]). Following antigen retrieval, the primary antibody to 11*β*-HSD1 and 11*β*-HSD2 was used at a 1 : 100 and 1 : 50 dilution, respectively, and the species-specific secondary IgG was diluted to 1 : 5000. The primary antibody was withheld from negative controls and these were incubated in diluent alone. Staining was quantified following the criteria detailed by [@bib62]. Normal and tumour sections were scored independently by two investigators (SSP and NC) and graded as no (0), weak (1), moderate (2), or strong (3) staining.

Database search
---------------

A publicly available repository (<http://www.proteinatlas.org>) was used to access immunohistochemical data of 11*β*-HSDs staining, as reported in [Supplementary Table 1](#sup1){ref-type="supplementary-material"}. GENT (<http://medicalgenome.kribb.re.kr/GENT>), a *G*ene *E*xpression across *N*ormal and *T*umour tissue database, was used to interrogate mRNA expression in both cell lines and tissues.

Immunofluorescence microscopy
-----------------------------

Immunofluorescence microscopy was performed as previously described ([@bib11]), but with minor modifications. Briefly, cells were cultured in four-well-plates (Nunc Cell-Culture Treated Multidishes, Thermo Fisher Scientific, Paisley, UK; Fisher Scientific UK Ltd, Loughborough, UK) in standard conditions. At 60% confluence, cells were fixed with 100% vol./vol. ice-cold methanol for 10 min at 4 °C and then incubated with 0.5 μg ml^−1^ Hoetstch staining (H6024, Sigma-Aldrich) for 30 min at 4 °C and then blocked with 5% wt/vol. BSA--PBS solution at 4 °C for 60 min. Samples were incubated overnight at 4 °C with anti-11*β*-HSD1/2 primary antibody at 1/100 dilution in 2% wt/vol BSA--PBS followed by FITC-conjugated species-specific IgG for 1 h at 1/1000 dilution in 2% wt/vol. BSA--PBS. All intermediate washing steps were performed with PBS. Images were taken with a fluorescence microscope (EVOS FLoid Cell Imaging Station, Life Technologies, Cramlington, UK).

Adhesion and cohesion assays in two- and three-dimensional models
-----------------------------------------------------------------

To quantify the strength of 2D cell-to-cell adhesion in monolayers, we undertook dispase-based cell dissociation assays, as described previously ([@bib6]).

For 3D cohesion assays, MCAs were first analysed by phase-contrast microscopy to check for their compact appearance. Then, the MCAs were sedimented in 15 ml tubes and subjected to mechanical stress by pipetting 20 times with a 5 ml pipette. The residual spheroids were sedimented at 1G and the ratio of the number of MCA-forming cells and the number of single cells in suspension was calculated. The ratio of total to single cells was indicative of intercellular adhesive strength ([@bib7]).

For scattering assays, the surface (pixels) covered by cells originating from disaggregating MCAs were measured and then those values were normalised against the total number of cells.

Statistical analysis
--------------------

The statistical significance of the data was evaluated by the Student's *t*-test. Data are reported as mean±standard deviation and differences were considered to be significant when *p* was \<0.05.

Results
=======

Tumour-derived cortisol inhibits lymphocyte proliferation
---------------------------------------------------------

We and others have shown that tumour-specific CD8^+^ T lymphocyte activity is suppressed by factors produced within the tumour microenvironment ([@bib1]; [@bib24]; [@bib3]). To test whether the production of cortisol by tumour cells had paracrine effects that could target tumour-specific immune responses, we exposed naïve tumour-specific CD8^+^ T lymphocytes (CL4 cells) to conditioned media from cortisol-producing II-3 malignant epidermal cells ([@bib10]; [@bib31]) stimulated with ACTH and, in parallel, treated lymphocytes with hydrocortisone. The data showed that the rate of proliferation of CL4 CD8^+^ T lymphocytes was significantly reduced in the presence of conditioned media from ACTH-stimulated II-3 cells; the effect was inhibited in the presence of the glucocorticoid receptor (GR) inhibitor RU486 thereby confirming that such inhibition was specific to cortisol ([Figure 1A](#fig1){ref-type="fig"}). In control experiments we confirmed that hydrocortisone directly inhibited the rate of proliferation among naïve mouse tumour-specific CD8^+^ T cells primed *in vitro* using plate-bound anti-CD3 and anti CD28 mAb in a dose-dependent manner ([Supplementary Figure 1](#sup1){ref-type="supplementary-material"}). We extended these observations to examine whether unstimulated malignant cells from other tissue-types synthesised cortisol *de novo* and, if so, whether conditioned media from these same cells could inhibit naïve tumour-specific CD8^+^ T lymphocyte proliferation. All (12 out of 12) of the malignant cell lines from the prostate, bladder, breast, colorectum, kidney and pancreas ([Supplementary Figure 2A](#sup1){ref-type="supplementary-material"}) produced detectable levels of cortisol (0.1--8.4 ng ml^−1^) at baseline; 11 of 12 reduced the proliferation rate of CD8^+^ T lymphocytes and one cell line from bladder cancer (T24) increased the proliferation ([Supplementary Figure 1](#sup1){ref-type="supplementary-material"}). Cell lines of colorectal origin (HT29, SW620, SWH80) produced little, if any, cortisol but caused marked inhibition of proliferation ([Figure 1B](#fig1){ref-type="fig"}) suggesting that there may be other mechanisms of immune suppression/regulation exhibited by this cell type (see Discussion). When the data relating to the colorectal lines were excluded, there was a strong correlation between basal cortisol production and inhibition of lymphocyte proliferation (Spearman's correlation coefficient was 0.89; [Figure 1C](#fig1){ref-type="fig"}). Collectively, the data demonstrate that a large variety of cancer cells from different tissues produce active cortisol and inhibit tumour-specific CD8^+^ T lymphocyte proliferation *in vitro*.

Cortisol interconversion is modulated by 11***β***-hydroxysteroid dehydrogenases
--------------------------------------------------------------------------------

The above experiments demonstrated that the production of basal levels of cortisol was common in tumour cells. Next, we wanted to test whether the interconversion of cortisol could be modulated locally and, to this end, we used HaCaT skin keratinocytes and their mutant c-Ha-ras-transfected clones ([Figure 1A](#fig1){ref-type="fig"}). All clones consistently secreted cortisol under basal conditions and increased steroid production following stimulation with ACTH; c-Ha-ras-transfected clones that formed malignant SCCs following transplantation to athymic mice (II-3, RT-3) produced significantly more cortisol following ACTH stimulation than their non-tumourigenic counterparts (HaCaT) and c-Ha-ras-transfected clones that formed benign epidermoid cysts on transplantation to athymic mice (I-7). Other SCC cells derived from tumour samples were also investigated and were found to secrete cortisol under basal conditions ([Supplementary Figure 3](#sup1){ref-type="supplementary-material"}).

Previous studies demonstrated that HaCaT expressed active 11*β*-HSD1 and 11*β*-HSD2 enzymes ([@bib9]; [@bib31]). In this study, we extended these observations and demonstrated that benign (I-7) and malignant (II-3, RT-3) c-Ha-ras clones also expressed functional 11*β*-HSD1 and 11*β*-HSD2 ([Figures 2B--D](#fig2){ref-type="fig"}). Silencing of 11*β*-HSD1 correlated with a reduced ability of malignant cells to convert cortisone to active cortisol; this was progressively restored by an increase of 11*β*-HSD1 expression ([Figure 2C](#fig2){ref-type="fig"}). Similarly, 11*β*-HSD2 controlled the inactivation of cortisol in a dose-dependent fashion ([Figure 2D](#fig2){ref-type="fig"}). 11*β*-HSD1 and 11*β*-HSD2 were also expressed in SCCs (*n*=10) and melanomas (*n*=10) ([Figures 2E and F](#fig2){ref-type="fig"}). Taken together, the data demonstrate that skin cancer cells have the capacity to regulate cortisol levels through the expression of 11*β*-HSD1 and 11*β*-HSD2.

Expression of 11***β***-HSD enzymes is altered in cancers
---------------------------------------------------------

To investigate whether the enzymes modulating the local concentration of active steroid were dysregulated in malignancy, we examined the expression of 11*β*-HSD1/2 in normal and malignant tissues using publicly available data sets. According to GENT data sets, mRNA levels encoding for 11*β*-HSD1 (HSD11B1) and 11*β*-HSD2 (HSD11B2) differed in normal and neoplastic tissues. Therefore, we examined the expression profile of these enzymes at the protein level using Protein Atlas (<http://www.proteinatlas.org>). Fifteen normal tissue types (*n*=126; controls) were matched with their malignant counterparts (*n*=315; cancers); a total of 441 different samples were examined in which there were 590 cancer specimens ([Supplementary Table 1](#sup1){ref-type="supplementary-material"}). Twelve of 15 (80%) cancer types had significant changes (*P*\<0.05) of 11*β*-HSDs staining ([Figure 3](#fig3){ref-type="fig"}). In the main, there was an inverse relationship in the pattern of expression of 11*β*-HSD1 and 11*β*-HSD2, with either an increase in 11*β*-HSD1 staining (cervical, glial, urotelial) or decreased expression of 11*β*-HSD2 (colon, lung, stomach, thyroid), or both (endometrial, head and neck, renal, prostate). 11*β*-HSD1 was also upregulated in liver cancer with a *p*-value close to significance (50% overall increase compared to control tissue, *P*=0.069). Exceptions to the above generalisation included breast and pancreatic cancers which did not show major changes compared to matched normal tissues and cancer of the testis which showed increased 11*β*-HSD2 levels. Collectively, these results strongly suggest that dysregulation of the enzymes associated with local cortisol interconversion is a common feature of solid tumours.

Local cortisol levels regulate keratinocyte invasion, cohesion and scattering in a two- and three-dimensional models of epidermal cancer
----------------------------------------------------------------------------------------------------------------------------------------

We hypothesised that the local production and degradation of cortisol could influence tumour progression. First, we demonstrated that cortisone, cortisol (hydrocortisone when used as a medication) and ACTH acted directly to increase the invasion of epidermal keratinocytes ([Figures 4A--D](#fig4){ref-type="fig"}). The effect was most striking among II-3 cells where there was a statistical increase in invasion following treatment with hydrocortisone and ACTH. The effect was not seen in HaCaT, I-7 or RT-3 cells.

Hydrocortisone has been shown to exert pro-adhesive effects in normal keratinocytes ([@bib38]). As inhibition of 11*β*-HSD2 leads to increased cortisol levels in the culture medium, a dispase-based assay was undertaken to investigate whether inhibition of 11*β*-HSD2 altered intercellular adhesion in malignant epidermal cells. For this experiment we opted for a pharmacological block of the enzyme using 18*β*-GA because this inhibitor, unlike siRNAs, allowed achieving consistent levels of 11*β*-HSD2 activity throughout the experimental period (not shown). As shown in [Figures 5A--C](#fig5){ref-type="fig"}, keratinocyte monolayers displayed increased cell--cell adhesive strength (i.e., resistance to cell--cell detachment) in the presence of the 11*β*-HSD2 inhibitor 18*β*-GA. 11*β*-HSD2 activity was also examined in a three-dimensional model of cell adhesion. Multicellular aggregates were prepared in the presence or absence of 18*β*-GA ([Figures 5D and E](#fig5){ref-type="fig"}) and while the number of cells that aggregated together in suspension and formed MCAs after 24 h of incubation was similar in both groups (not shown), intercellular cohesion of mature (24 h) MCAs, as quantified by the release of single cells from the spheroids after mechanical stress, was higher in MCAs cultured in the presence of 18*β*-GA ([Figure 5H](#fig5){ref-type="fig"}). The MCAs were left to attach and disaggregate on a collagen substrate in 18*β*-GA-free medium and migration from the core of the cell aggregate was measured in a scattering assay. Control MCAs were almost entirely dissolved 6 h after seeding ([Figure 5F](#fig5){ref-type="fig"}) whereas MCAs grown in the presence of 18*β*-GA displayed a reduced ability to scatter and migrate from the spheroids after attachment on collagen substrates ([Figure 5G](#fig5){ref-type="fig"}) and were able to cover only ∼55% of the area compared to control MCAs ([Figure 5I](#fig5){ref-type="fig"}).

Taken together, the data demonstrate that pharmacological modulation of cortisol degradation via 11*β*-HSD2 inhibition influences cell adhesion and three-dimensional intercellular cohesion of malignant keratinocytes.

Expression of 11*β*-HSD2 in skin and its downregulation in squamous cell carcinoma
----------------------------------------------------------------------------------

The above results suggested that 11*β*-HSD2 expression was important to the bioavailability of tumour-derived cortisol. However, previous research on the expression of 11*β*-HSD2 in the human integument has given conflicting results ([@bib56]; [@bib60]; [@bib53]). In this study, we used a rabbit antibody against the residues 261--405 of human 11*β*-HSD2 at a 1 : 100 dilution, a concentration at which normal skin displayed strong staining ([Supplementary Figure 4](#sup1){ref-type="supplementary-material"}). Using tissue arrays, immunohistochemical expression of 11*β*-HSD2 was examined in 40 cases of SCC and 8 normal skin controls ([Figure 6](#fig6){ref-type="fig"}). The intensity of 11*β*-HSD2 staining in the malignant tissues was consistently less than control tissues. Eleven of 40 SCCs (27.5%) displayed no staining while staining intensity was weak to moderate in a further 25 samples (62.5%). Overall, the 11*β*-HSD2 staining score in SCC was statistically less (*P*\<0.05) than in the controls ([Supplementary Figure 5](#sup1){ref-type="supplementary-material"}). We therefore conclude that the expression of 11*β*-HSD2, a key enzyme in the local control of keratinocyte-derived cortisol, is significantly reduced in SCCs of the skin.

Taken together, the data demonstrate that cancer cells produce cortisol irrespective of their tissue of origin. Furthermore, 11*β*-HSD2-mediated regulation of tumour-derived cortisol potentially plays an important role in the pathobiology of epidermal malignancy.

Discussion
==========

This study presents a series of observations that demonstrate an important role for the GC system, and specifically for 11*β*-HSD2, in the physiology of normal and malignant epithelial cells. First, we show that cortisol production is a common feature of a broad spectrum of cancers and that cancer-derived cortisol inhibits CD8^+^ cytotoxic T lymphocyte proliferation in a GR-specific fashion. Second, we demonstrate that 11*β*-HSD1/2 expression is altered in many different cancer types in a fashion that is predicted to lead to a pro-cortisol-producing phenotype. Third, we establish that normal human skin tissues express detectable levels of 11*β*-HSD2 and that levels are reduced in SCCs. Fourth, we demonstrate *in vitro* that 11*β*-HSD2 is synthesised by human malignant keratinocytes under basal conditions and its expression and activity regulate both the production and inter-conversion of active cortisol. Finally, we show that 11*β*-HSD2 modulates intercellular adhesion and that inhibition of 11*β*-HSD2 by 18*β*-GA increases intercellular cohesion.

A major finding of this study was that cancer cells produce cortisol regardless of their tissue of origin, strongly supporting the view that a cancer-associated GC system is active in malignancy. Not only was cortisol production enhanced by ACTH treatment but also, analysis of CD8^+^ T cell responses revealed a linear correlation between basal cortisol levels in supernatants from cancer cells and inhibition of lymphocyte proliferation. Given the importance of T-cell-mediated responses in the progression of cancer, as well as its prognostic relevance ([@bib32]; [@bib61]), our data suggest that the production of cortisol by malignant cells may have an important immunoregulatory function. These findings are consistent with [@bib45] who showed that tumour-derived GCs from colon cancer induced suppression of T-cell activation. The present study, however, is the first to extend this concept to a broad spectrum of solid tumours. It is also intriguing that under our experimental conditions, colorectal cancer cells (HT29, SW620, SWH80) were the only cell type not to show a correlation between cortisol production and inhibition of CD8 T lymphocytes. Specifically, these cells produced low amounts of basal cortisol but concurrently reduced T-cell proliferation. We have shown previously that other tumour-derived molecules such as prostaglandins may be involved in the immune regulation of CD8 cells in cancer ([@bib1]; [@bib3]).

In the past two decades, the intracellular inter-conversion of inactive and active steroids by the 11*β*-HSDs has emerged as a key mechanism underlying tissue-specific regulation of GC action. In non-adrenal tissues, 11*β*-HSDs have been shown to play a crucial role in the control of basic physiological functions, as well as in disease processes such as osteoporosis ([@bib12]), insulin-resistance ([@bib40]), chronic periodontitis ([@bib37]) and cancer ([@bib41]; [@bib64]). With regard to squamous epithelia, a number of studies from Slominski's group have supported the hypothesis that the skin has the potential to act as a neuroendocrine organ ([@bib46], [@bib47], [@bib48]). We have extended these observations and demonstrated that squamous epithelium lining the oral cavity acts as a corticosteroid-producing system and that alteration of 11*β*-HSDs in oral keratinocytes may play an important role in disease ([@bib10]). However, while studies addressing the function of 11*β*-HSDs in epidermal tissues support a key role for 11*β*-HSD type 1 in epidermal biology and pathophysiology ([@bib19]; [@bib20]; [@bib52]; [@bib56]; [@bib22]; [@bib28]; [@bib54]; [@bib57]), there is some disagreement about the putative expression and function of 11*β*-HSD type 2 ([@bib9]; [@bib56]; [@bib60]; [@bib53]). In the reports by Tiganescu *et al* (2011) and [@bib53], for example, the expression of 11*β*-HSD2 could not be demonstrated in human skin suggesting that keratinocytes cannot de-activate cortisol. In the present study, we demonstrated 11*β*-HSD2 in normal skin specimens, findings that are consistent with our published data showing 11*β*-HSD2 at both the mRNA and protein levels in keratinocytes. We conclude that 11*β*-HSD2 is present in epidermal keratinocytes.

To the best of our knowledge, the data reported in the present study are the first to show that 11*β*-HSD2 is not only expressed by epidermal keratinocytes but, also, that the pharmacological manipulation of 11*β*-HSD2 modulates cortisol levels and regulates certain cellular functions. The question remains, however, as to whether 11*β*-HSD2 can be modified for therapeutic benefit. Interestingly, it has been shown recently that 18*β*-GA, administered either prophylactically or therapeutically, induces a dramatic reduction in bone loss using a mouse model of periodontitis ([@bib44]). The authors suggested that this effect was independent of GC because a downregulation of 11*β*-HSD2 mRNA was not seen. 18*β*-GA, however, is known to impair 11*β*-HSD2 function by blocking enzymatic activity rather than by inducing down-regulation at the transcriptional level ([@bib64]; [@bib33]). In view of our recent findings ([@bib10]), we tentatively suggest that 18*β*-GA may reduce tissue inflammation and limit the bone loss that occurs in periodontal disease by increasing local cortisol levels. Further studies, however, are required to verify this proposal.

Our data demonstrate that silencing of 11*β*-HSD1 correlates with a temporary decrease in the local bioavailability of active cortisol, which increases once 11*β*-HSD1 expression is restored. The reverse is true for 11*β*-HSD2 where expression of the enzyme inversely correlates with cortisol levels. Therefore, alteration of 11*β*-HSD1/2 expression and function is tightly linked to the levels of cortisol in the microenvironment. In the present study, we examined the expression of 11*β*-HSD enzymes in a broad spectrum of cancer-types using an open IHC database. We show that dysregulation of 11*β*-HSDs is common in a broad spectrum of cancer-types; the enzymes were either upregulated (11*β*-HSD1) or downregulated (11*β*-HSD2), or both, in 11 out of 15 cancer types from 315 cases; the trend was consistent with an increase in the bioavailability of local cortisol. In SCC of the skin, there was a significant downregulation of 11*β*-HSD2 compared to normal skin., findings that are in accord with results from colorectal ([@bib63]) and oral ([@bib10]) cancers, but contrast with osteosarcoma ([@bib4]) and ovarian cancer ([@bib55]). The subject has recently been extensively reviewed ([@bib2]).

Recently, it has been shown that corticosteroids suppress key components of the senescence-associated secretory phenotype (SASP) ([@bib26]). In epithelial cells, cellular senescence is a mechanism that suppresses the early stages of cancer development suggesting that tumour-derived cortisol may inhibit the anti-cancer activity of the SASP and favour cancer progression. By contrast, we have shown that the SASP of cancer-associated fibroblasts (CAFs) exerts pro-tumourigenic paracrine effects on malignant oral epithelial cells ([@bib29]; [@bib17]; [@bib18]). In these circumstances, cortisol produced by malignant epithelial cells would be expected to have paracrine tumour suppressive effects. Interestingly, our recent observations have shown that cortisol is produced by normal fibroblasts ([@bib10]) as well as cancer-associated fibroblasts (CAFs) (Cirillo N, unpublished observations). Studies are ongoing to investigate the role of cortisol in the tumour micro-environment and the inter-relationship between epithelial cells, fibroblasts and immune cells.

In conclusion, we report that a non-adrenal GC system is active in cancer and that the resulting cortisol production suppresses lymphocyte proliferation. Further, we show that 11*β*-HSD2 modulates intercellular cohesion and that inhibition of 11*β*-HSD2 leads to an increase of secreted cortisol in epidermal cells. 11*β*-HSD2 is downregulated in SCCs of the skin as well as in eight other cancer types. We suggest that 11*β*-HSD2 could be used as a potential biomarker of tumour progression and may be of value therapeutically by regulating local tissue concentrations of cortisol in skin disease.
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![Naïve TcR transgenic tumour antigen-specific CL4 CD8^+^ T lymphocytes were incubated for 24 h with supernatants of ACTH-treated II-3 cells in the presence of the GR inhibitor RU486, or without treatment (**A**). CD8^+^ lymphocytes were incubated with supernatants from 12 cancer cells with known basal cortisol production. The cells were counted after 24 h and their number was plotted against the corresponding cortisol levels in the supernatants (**B**, **C**). \*\**P*\<0.01. A full colour version of this figure is available at the *British Journal of Cancer* journal online.](bjc2017243f1){#fig1}

![Cortisol levels in the supernatant of un-stimulated cells (Bsl) and cells treated with 10 n[M]{.smallcaps} ACTH for 24 h (ACTH) were assessed by ELISA (**A**). Western blotting and immunofluorescence were undertaken to investigate the expression of 11*β*-HSD1 and 11*β*-HSD2 proteins (**B**). siRNA was used to transiently knockdown the expression of 11*β*-HSD1 (**C**) and 11*β*-HSD2 (**D**) in II-3 cells; in parallel, the protein level of these enzymes was assessed by western blotting. Silencing of 11*β*-HSD1 resulted in a reduced ability of II-3 to activate cortisone (100 n[M]{.smallcaps}) into cortisol (**C**). Silencing of 11*β*-HSD2 in HC-treated cells (100 n[M]{.smallcaps}) resulted in an increase in the concentration of active cortisol in supernatants (**D**). Both effects were transient and progressively reverted when the expression levels of 11*β*-HSDs were restored. Both enzymes were detectable by IHC in human skin cancers, namely SCC (**E**) and melanoma (**F**). \**P*\<0.05, \*\**P*\<0.01, ^\#^*P*\<0.005, \*^\#^*P*\<0.001. A full colour version of this figure is available at the *British Journal of Cancer* journal online.](bjc2017243f2){#fig2}

![Staining intensity of 11*β*-HSD1/2 using a publicly available data set featuring 15 different normal/malignant tissues was computed and illustrated by histogram. *P*-value of paired *t*-test is reported. Blue colour indicates upregulation whereas red colour indicates downregulation. A full colour version of this figure is available at the *British Journal of Cancer* journal online.](bjc2017243f3){#fig3}

![HaCaT (**A**), I-7 (**B**), II-3 (**C**) and RT-3 (**D**) were used for the invasion assay in the presence of 100 n[M]{.smallcaps} cortisone, 100 n[M]{.smallcaps} hydrocortisone, 10 n[M]{.smallcaps} ACTH or without treatment (Control). ANOVA statistical analysis was used to determine the significance of the results. The histograms show mean values of four independent experiments±standard deviation. \**P*\<0.05.](bjc2017243f4){#fig4}

![A dispase-based assay was undertaken to assess cell--cell adhesion strength in II-3 cells with or without treatment with 18*β*-glycyrrhetinic acid (**A**--**C**). Cohesion strength (**D**, **E**, **H**) and scattering (**F**, **G**, **I**) of 3D cellular aggregates in the presence or absence of 18*β*-GA was also assessed. \**P*\<0.05. A full colour version of this figure is available at the *British Journal of Cancer* journal online.](bjc2017243f5){#fig5}

![Staining of 11*β*-HSD2 at a 1 : 100 dilution was undertaken using tissue microarrays. The array is shown with (**A**) and without (**B**) IHC staining and shows cases of squamous cell carcinoma (*n*=40), normal skin tissues (*n*=8) and a positive control (melanoma). Typical aspects of normal (**C**, **E**) and cancerous (**D**, **F**) samples are reported at × 4 and × 20 magnification. \**P*\<0.05, \*\**P*\<0.01. A full colour version of this figure is available at the *British Journal of Cancer* journal online.](bjc2017243f6){#fig6}
